{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:18:04Z","timestamp":1787883484890,"version":"build-2784847793"},"reference-count":71,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ajog.2017.06.038","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T15:47:25Z","timestamp":1499356045000},"page":"578.e1-578.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3381-5057","authenticated-orcid":false,"given":"Ranjit","family":"Manchanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreeya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis C.","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephrat","family":"Levy-Lahad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Hopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Macinnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-1732","authenticated-orcid":false,"given":"Usha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Legood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2017.06.038_bib1","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1073\/pnas.1415979111","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","volume":"111","author":"Gabai-Kapara","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajog.2017.06.038_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jnci\/dju379","article-title":"Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial","volume":"107","author":"Manchanda","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2017.06.038_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2009.25.0712","article-title":"Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women","volume":"28","author":"Metcalfe","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.06.038_bib4","unstructured":"Nelson HD, Fu R, Goddard K, et\u00a0al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the us preventive services task force recommendation. Rockville (MD): Agency for Healthcare Research and Quality, US Department of Health and Human Services; 2013."},{"key":"10.1016\/j.ajog.2017.06.038_bib5","article-title":"Population screening for BRCA1\/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral","author":"Lieberman","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.ajog.2017.06.038_bib6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/jmedgenet-2015-103740","article-title":"Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1\/2 mutations","volume":"53","author":"Manchanda","year":"2016","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.ajog.2017.06.038_bib7","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/nbt1486","article-title":"Next-generation DNA sequencing","volume":"26","author":"Shendure","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ajog.2017.06.038_bib8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jnci\/dju380","article-title":"Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing","volume":"107","author":"Manchanda","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2017.06.038_bib9","series-title":"Jews in Britain: a snapshot from the 2001 census, vol. 1","author":"Graham","year":"2007"},{"key":"10.1016\/j.ajog.2017.06.038_bib10","series-title":"A\u00a0Portrait of Jewish Americans: Findings from a Pew Research Center Survey of US Jews","year":"2013"},{"key":"10.1016\/j.ajog.2017.06.038_bib11","unstructured":"Founder Populations and their contribution to our understanding of biology and history: lessons from the Jewish genome. Think tank on BRCA screening. Haifa, Israel 10\/7\/2016. Available at: https:\/\/www.foundergenomics.com\/. Accessed October 12, 2016."},{"key":"10.1016\/j.ajog.2017.06.038_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jmedgenet-2015-103077","article-title":"A\u00a0risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects","volume":"52","author":"Jervis","year":"2015","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.ajog.2017.06.038_bib13","series-title":"Guide to the methods of technology appraisal","year":"2008"},{"key":"10.1016\/j.ajog.2017.06.038_bib14","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","article-title":"Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment","volume":"113","author":"Havrilesky","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2017.06.038_bib15","series-title":"Clinical Guideline (CG81): advanced breast cancer: diagnosis and treatment","year":"2009"},{"key":"10.1016\/j.ajog.2017.06.038_bib16","series-title":"Early and locally advanced breast cancer: diagnosis and treatment: NICE Clinical Guideline, CG80","year":"2009"},{"key":"10.1016\/j.ajog.2017.06.038_bib17","series-title":"National costing report: early and locally advanced breast cancer\/Advanced breast cancer","year":"2009"},{"key":"10.1016\/j.ajog.2017.06.038_bib18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/erp.10.65","article-title":"Health-state utility values in breast cancer","volume":"10","author":"Peasgood","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ajog.2017.06.038_bib19","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2017.06.038_bib20","series-title":"Cancer incidence in the UK in 2011","year":"2014"},{"key":"10.1016\/j.ajog.2017.06.038_bib21","series-title":"Surveillance, Epidemiology, and End Results Program. Cancer stat facts: ovary cancer","year":"2014"},{"key":"10.1016\/j.ajog.2017.06.038_bib22","series-title":"Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer","year":"2014"},{"issue":"suppl2","key":"10.1016\/j.ajog.2017.06.038_bib23","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1038\/sj.bjc.6605401","article-title":"What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable?","volume":"101","author":"Abdel-Rahman","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2017.06.038_bib24","series-title":"Guide to the methods of technology appraisal: N1618","year":"2008"},{"key":"10.1016\/j.ajog.2017.06.038_bib25","series-title":"Social value judgements: principles for the development of NICE guidance (NICE)","year":"2008"},{"key":"10.1016\/j.ajog.2017.06.038_bib26","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness: the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.06.038_bib27","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.163.14.1637","article-title":"What is the price of life and why doesn\u2019t it increase at the rate of inflation?","volume":"163","author":"Ubel","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ajog.2017.06.038_bib28","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta13290","article-title":"Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making","volume":"13","author":"Andronis","year":"2009","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ajog.2017.06.038_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1524-4733.2005.08101.x","article-title":"Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty","volume":"8","author":"Briggs","year":"2005","journal-title":"Value Health"},{"key":"10.1016\/j.ajog.2017.06.038_bib30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMp0708558","article-title":"Does preventive care save money? Health economics and the presidential candidates","volume":"358","author":"Cohen","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.06.038_bib31","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/gim.2016.29","article-title":"Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations","volume":"18","author":"D\u2019Andrea","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.ajog.2017.06.038_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djv033","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction","volume":"107","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2017.06.038_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2017.06.038_bib34","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2017.06.038_bib35","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ajog.2017.06.038_bib36","doi-asserted-by":"crossref","first-page":"djv217","DOI":"10.1093\/jnci\/djv217","article-title":"RE: Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction","volume":"107","author":"Chai","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2017.06.038_bib37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/cge.12149","article-title":"Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers","volume":"85","author":"Laitman","year":"2014","journal-title":"Clin Genet"},{"key":"10.1016\/j.ajog.2017.06.038_bib38","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1471-0528.2011.02920.x","article-title":"Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status","volume":"118","author":"Manchanda","year":"2011","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2017.06.038_bib39","first-page":"CD002748","article-title":"Prophylactic mastectomy for the prevention of breast cancer","author":"Lostumbo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2017.06.038_bib40","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","article-title":"Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer","volume":"23","author":"Madalinska","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.06.038_bib41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2010.12.326","article-title":"The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation","volume":"121","author":"Finch","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2017.06.038_bib42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0090-8258(03)00072-6","article-title":"Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy","volume":"89","author":"Robson","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2017.06.038_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/fon.15.278","article-title":"Genetic screening for gynecological cancer: where are we heading?","volume":"12","author":"Manchanda","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.ajog.2017.06.038_bib44","series-title":"\u2018Screen more\u2019 for cancer risk genes: British Broadcasting Corporation","author":"Gallagher","year":"2014"},{"key":"10.1016\/j.ajog.2017.06.038_bib45","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/jnci\/dju420","article-title":"Precision medicine meets public health: population screening for BRCA1 and BRCA2","volume":"107","author":"Levy-Lahad","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2017.06.038_bib46","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1055-9965.EPI-09-0171","article-title":"Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent","volume":"18","author":"Evans","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2017.06.038_bib47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2017.06.038_bib48","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.06.038_bib49","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.06.038_bib50","series-title":"Breast Cancer Incidence Statistics UK 2009-2011: Breast Cancer (C50), Average Number of New Cases per Year and Age-Specific Incidence Rates, Females, UK, 2009-2011","year":"2012"},{"key":"10.1016\/j.ajog.2017.06.038_bib51","series-title":"Cancer registration statistics, England","year":"2013"},{"key":"10.1016\/j.ajog.2017.06.038_bib52","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1471-0528.2011.03257.x","article-title":"Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis","volume":"119","author":"Manchanda","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2017.06.038_bib53","series-title":"Ovarian cancer incidence statistics: 2011","year":"2014"},{"key":"10.1016\/j.ajog.2017.06.038_bib54","series-title":"Unit costs of health and social care 2011","author":"Curtis","year":"2011"},{"key":"10.1016\/j.ajog.2017.06.038_bib55","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.2013.51.3226","article-title":"Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer","volume":"32","author":"Schwartz","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.06.038_bib56","series-title":"NHS Reference Costs 2012-2013","year":"2013"},{"key":"10.1016\/j.ajog.2017.06.038_bib57","unstructured":"British National Formulary. British National Formulary 67. London: BMJ Group, and the Pharmaceutical Press (Royal Pharmaceutical Society of Great Britain); 2014."},{"key":"10.1016\/j.ajog.2017.06.038_bib58","series-title":"Ovarian cancer: the recognition and initial management of ovarian cancer, vol CG122","year":"2011"},{"key":"10.1016\/j.ajog.2017.06.038_bib59","unstructured":"Incisive Health and Cancer Research UK. Saving lives, averting costs. An analysis of the financial implications of achieving earlier diagnosis of colorectal, lung and ovarian cancer 2014. Available at: http:\/\/www.cancerresearchuk.org\/sites\/default\/files\/saving_lives_averting_costs.pdf. Accessed August 1, 2017."},{"key":"10.1016\/j.ajog.2017.06.038_bib60","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10549-010-1043-4","article-title":"Comparative effectiveness of screening and prevention strategies among BRCA1\/2-affected mutation carriers","volume":"125","author":"Grann","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajog.2017.06.038_bib61","article-title":"End of life Care","year":"2008"},{"key":"10.1016\/j.ajog.2017.06.038_bib62","series-title":"Saving lives, averting costs: an analysis of the financial implications of achieving earlier diagnosis of colorectal, lung and ovarian cancer","year":"2014"},{"key":"10.1016\/j.ajog.2017.06.038_bib63","doi-asserted-by":"crossref","first-page":"v","DOI":"10.3310\/hta15340","article-title":"The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation","volume":"15","author":"Robertson","year":"2011","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ajog.2017.06.038_bib64","series-title":"Breast cancer screening guidelines for women","year":"2016"},{"key":"10.1016\/j.ajog.2017.06.038_bib65","series-title":"Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer","year":"2013"},{"key":"10.1016\/j.ajog.2017.06.038_bib66","series-title":"Breast screening programme, England 2008-09","author":"Waldron","year":"2010"},{"key":"10.1016\/j.ajog.2017.06.038_bib67","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1158\/1055-9965.EPI-11-1196","article-title":"Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined","volume":"21","author":"Heijnsdijk","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ajog.2017.06.038_bib68","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/jmg.2004.024133","article-title":"Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies","volume":"42","author":"Antoniou","year":"2005","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.ajog.2017.06.038_bib69","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2005.04.3273","article-title":"Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials","volume":"24","author":"Wapnir","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.06.038_bib70","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1200\/JCO.2008.19.8424","article-title":"Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer","volume":"27","author":"Anderson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.06.038_bib71","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/cncr.21359","article-title":"Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies","volume":"104","author":"Gennari","year":"2005","journal-title":"Cancer"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817308426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817308426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:14:01Z","timestamp":1757589241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937817308426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0002937817308426"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2017.06.038","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2017.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}